SGMOQ — SANGAMO THERAPEUTICS, INC
—
OTC ·
Health Care ·
Biotechnology ·
CIK 1001233 ·
Last close
$0.16
Market Cap
—
52W High
$0.25
52W Low
$0.03
ADV30
3,781,741
Next earnings
2026-08-24
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2024 | 49,412,000 | 49,412,000 | 10,631,000 | 10,672,000 | 101,635,000 | 41,918,000 | 78,865,000 |
TTM Snapshot
Revenues TTM
$49,412,000
NetIncome TTM
$10,672,000
OpCashFlow TTM
$0
Assets (Latest)
$101,635,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMGN | AMGEN INC | $229.53B | $425.28 | — |
| GILD | GILEAD SCIENCES, INC. | $177.86B | $143.44 | — |
| ARGX | ARGENX SE | $61.75B | $992.99 | — |
| RVMD | Revolution Medicines, Inc. | $46.30B | $216.00 | — |
| BIIB | BIOGEN INC. | $31.41B | $212.55 | — |
News headlines (Yahoo Finance, 1h cache)
PTC takes a chance on Sangamo’s Fabry disease gene therapy
2026-08-13 11:10 · Yahoo
PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program
2026-08-12 20:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.